

Steven P Balk

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4572283/publications.pdf>

Version: 2024-02-01

129
papers

12,871
citations

30070

54
h-index

23533

111
g-index

134
all docs

134
docs citations

134
times ranked

13251
citing authors

#	ARTICLE	IF	CITATIONS
1	Mutation of the Androgen-Receptor Gene in Metastatic Androgen-Independent Prostate Cancer. <i>New England Journal of Medicine</i> , 1995, 332, 1393-1398.	27.0	1,144
2	Increased Expression of Genes Converting Adrenal Androgens to Testosterone in Androgen-Independent Prostate Cancer. <i>Cancer Research</i> , 2006, 66, 2815-2825.	0.9	967
3	Androgen Receptor Regulates a Distinct Transcription Program in Androgen-Independent Prostate Cancer. <i>Cell</i> , 2009, 138, 245-256.	28.9	797
4	Extreme Th1 bias of invariant V α 24J β Q T cells in type 1 diabetes. <i>Nature</i> , 1998, 391, 177-181.	27.8	639
5	Biology of Prostate-Specific Antigen. <i>Journal of Clinical Oncology</i> , 2003, 21, 383-391.	1.6	524
6	Requirements for CD1d Recognition by Human Invariant V α 24+ CD4 α CD8 α T Cells. <i>Journal of Experimental Medicine</i> , 1997, 186, 109-120.	8.5	509
7	Adipose Tissue Invariant NKT Cells Protect against Diet-Induced Obesity and Metabolic Disorder through Regulatory Cytokine Production. <i>Immunity</i> , 2012, 37, 574-587.	14.3	419
8	Androgen Receptor Gene Expression in Prostate Cancer Is Directly Suppressed by the Androgen Receptor Through Recruitment of Lysine-Specific Demethylase 1. <i>Cancer Cell</i> , 2011, 20, 457-471.	16.8	387
9	Intratumoral <i>De Novo</i> Steroid Synthesis Activates Androgen Receptor in Castration-Resistant Prostate Cancer and Is Upregulated by Treatment with CYP17A1 Inhibitors. <i>Cancer Research</i> , 2011, 71, 6503-6513.	0.9	383
10	Loss of IFN- γ Production by Invariant NK T Cells in Advanced Cancer. <i>Journal of Immunology</i> , 2001, 167, 4046-4050.	0.8	343
11	AR, the cell cycle, and prostate cancer. <i>Nuclear Receptor Signaling</i> , 2008, 6, nrs.06001.	1.0	300
12	Androgen receptor splice variant-7 expression emerges with castration resistance in prostate cancer. <i>Journal of Clinical Investigation</i> , 2018, 129, 192-208.	8.2	266
13	Androgens Induce Prostate Cancer Cell Proliferation through Mammalian Target of Rapamycin Activation and Post-transcriptional Increases in Cyclin D Proteins. <i>Cancer Research</i> , 2006, 66, 7783-7792.	0.9	260
14	Intense Androgen-Deprivation Therapy With Abiraterone Acetate Plus Leuprolide Acetate in Patients With Localized High-Risk Prostate Cancer: Results of a Randomized Phase II Neoadjuvant Study. <i>Journal of Clinical Oncology</i> , 2014, 32, 3705-3715.	1.6	220
15	Bicalutamide Functions as an Androgen Receptor Antagonist by Assembly of a Transcriptionally Inactive Receptor. <i>Journal of Biological Chemistry</i> , 2002, 277, 26321-26326.	3.4	203
16	Actin-containing matrix associated with the plasma membrane of murine tumour and lymphoid cells. <i>Nature</i> , 1981, 289, 139-144.	27.8	202
17	Androgen receptor phosphorylation and stabilization in prostate cancer by cyclin-dependent kinase 1. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006, 103, 15969-15974.	7.1	183
18	Tyrosine Kinases Expressed in Vivo by Human Prostate Cancer Bone Marrow Metastases and Loss of the Type 1 Insulin-Like Growth Factor Receptor. <i>American Journal of Pathology</i> , 1999, 155, 1271-1279.	3.8	172

#	ARTICLE	IF	CITATIONS
19	Rapid Induction of Androgen Receptor Splice Variants by Androgen Deprivation in Prostate Cancer. <i>Clinical Cancer Research</i> , 2014, 20, 1590-1600.	7.0	165
20	Abiraterone Treatment in Castration-Resistant Prostate Cancer Selects for Progesterone Responsive Mutant Androgen Receptors. <i>Clinical Cancer Research</i> , 2015, 21, 1273-1280.	7.0	152
21	Reactivation of Androgen Receptor-Regulated <i>TPRSS2:ERG</i> Gene Expression in Castration-Resistant Prostate Cancer. <i>Cancer Research</i> , 2009, 69, 6027-6032.	0.9	141
22	Redirecting abiraterone metabolism to fine-tune prostate cancer anti-androgen therapy. <i>Nature</i> , 2016, 533, 547-551.	27.8	138
23	SOX9 drives WNT pathway activation in prostate cancer. <i>Journal of Clinical Investigation</i> , 2016, 126, 1745-1758.	8.2	138
24	Tumor Microenvironment-Derived NRG1 Promotes Antiandrogen Resistance in Prostate Cancer. <i>Cancer Cell</i> , 2020, 38, 279-296.e9.	16.8	135
25	Intratumoral androgen biosynthesis in prostate cancer pathogenesis and response to therapy. <i>Endocrine-Related Cancer</i> , 2011, 18, R175-R182.	3.1	131
26	Adoptive Transfer of Invariant NKT Cells as Immunotherapy for Advanced Melanoma: A Phase I Clinical Trial. <i>Clinical Cancer Research</i> , 2017, 23, 3510-3519.	7.0	130
27	ARv7 Represses Tumor-Suppressor Genes in Castration-Resistant Prostate Cancer. <i>Cancer Cell</i> , 2019, 35, 401-413.e6.	16.8	127
28	AR and ER Interaction with a p21-Activated Kinase (PAK6). <i>Molecular Endocrinology</i> , 2002, 16, 85-99.	3.7	119
29	EZH2 inhibition activates a dsRNA-STING interferon stress axis that potentiates response to PD-1 checkpoint blockade in prostate cancer. <i>Nature Cancer</i> , 2021, 2, 444-456.	13.2	118
30	Lysine-Specific Demethylase 1 Has Dual Functions as a Major Regulator of Androgen Receptor Transcriptional Activity. <i>Cell Reports</i> , 2014, 9, 1618-1627.	6.4	115
31	Cabozantinib Eradicates Advanced Murine Prostate Cancer by Activating Antitumor Innate Immunity. <i>Cancer Discovery</i> , 2017, 7, 750-765.	9.4	112
32	Role of Androgen Receptor Variants in Prostate Cancer: Report from the 2017 Mission Androgen Receptor Variants Meeting. <i>European Urology</i> , 2018, 73, 715-723.	1.9	105
33	Identification of hypoxia-inducible factor-1? (HIF-1?) polymorphism as a mutation in prostate cancer that prevents normoxia-induced degradation. <i>Prostate</i> , 2005, 63, 215-221.	2.3	98
34	Androgen Receptor Serine 81 Phosphorylation Mediates Chromatin Binding and Transcriptional Activation. <i>Journal of Biological Chemistry</i> , 2012, 287, 8571-8583.	3.4	94
35	Transcriptional mediators of treatment resistance in lethal prostate cancer. <i>Nature Medicine</i> , 2021, 27, 426-433.	30.7	90
36	CD1d-restricted T cells regulate dendritic cell function and antitumor immunity in a granulocyte-macrophage colony-stimulating factor-dependent fashion. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2003, 100, 8874-8879.	7.1	89

#	ARTICLE	IF	CITATIONS
37	Selective activation, expansion, and monitoring of human iNKT cells with a monoclonal antibody specific for the TCR α -chain CDR3 loop. <i>European Journal of Immunology</i> , 2008, 38, 1756-1766.	2.9	89
38	Clonal Progression of Prostate Cancers from Gleason Grade 3 to Grade 4. <i>Cancer Research</i> , 2013, 73, 1050-1055.	0.9	85
39	Phosphoinositide 3-Kinase Pathway Activation in Phosphate and Tensin Homolog (PTEN)-deficient Prostate Cancer Cells Is Independent of Receptor Tyrosine Kinases and Mediated by the p110 β and p110 δ Catalytic Subunits. <i>Journal of Biological Chemistry</i> , 2010, 285, 14980-14989.	3.4	82
40	Galeterone Prevents Androgen Receptor Binding to Chromatin and Enhances Degradation of Mutant Androgen Receptor. <i>Clinical Cancer Research</i> , 2014, 20, 4075-4085.	7.0	81
41	Neoadjuvant Enzalutamide Prior to Prostatectomy. <i>Clinical Cancer Research</i> , 2017, 23, 2169-2176.	7.0	80
42	The altered expression of MiR-221/222 and MiR-23b/27b is associated with the development of human castration resistant prostate cancer. <i>Prostate</i> , 2012, 72, 1093-1103.	2.3	79
43	Chromatin binding of FOXA1 is promoted by LSD1-mediated demethylation in prostate cancer. <i>Nature Genetics</i> , 2020, 52, 1011-1017.	21.4	78
44	Recruitment of β -Catenin by Wild-Type or Mutant Androgen Receptors Correlates with Ligand-Stimulated Growth of Prostate Cancer Cells. <i>Molecular Endocrinology</i> , 2004, 18, 2388-2401.	3.7	77
45	Expression of PD-L1 in Hormone-naïve and Treated Prostate Cancer Patients Receiving Neoadjuvant Abiraterone Acetate plus Prednisone and Leuprolide. <i>Clinical Cancer Research</i> , 2017, 23, 6812-6822.	7.0	77
46	PTEN-Deficient Tumors Depend on AKT2 for Maintenance and Survival. <i>Cancer Discovery</i> , 2014, 4, 942-955.	9.4	75
47	Tumor susceptibility gene 101 protein represses androgen receptor transactivation and interacts with p300. <i>Oncogene</i> , 1999, 86, 689-696.		71
48	Effects of the Administration of High-Dose Interleukin-2 on Immunoregulatory Cell Subsets in Patients with Advanced Melanoma and Renal Cell Cancer. <i>Clinical Cancer Research</i> , 2007, 13, 2100-2108.	7.0	71
49	ATM Loss Confers Greater Sensitivity to ATR Inhibition Than PARP Inhibition in Prostate Cancer. <i>Cancer Research</i> , 2020, 80, 2094-2100.	0.9	71
50	Increased PAK6 expression in prostate cancer and identification of PAK6 associated proteins. <i>Prostate</i> , 2008, 68, 1510-1516.	2.3	69
51	Androgen Receptor Tumor Suppressor Function Is Mediated by Recruitment of Retinoblastoma Protein. <i>Cell Reports</i> , 2016, 17, 966-976.	6.4	66
52	Activation of β -Catenin Signaling in Prostate Cancer by Peptidyl-Prolyl Isomerase Pin1-Mediated Abrogation of the Androgen Receptor- β -Catenin Interaction. <i>Molecular and Cellular Biology</i> , 2006, 26, 929-939.	2.3	65
53	Defective NKT Cell Activation by CD1d+ TRAMP Prostate Tumor Cells Is Corrected by Interleukin-12 with α -Galactosylceramide. <i>PLoS ONE</i> , 2010, 5, e11311.	2.5	57
54	The Cistrome and Gene Signature of Androgen Receptor Splice Variants in Castration Resistant Prostate Cancer Cells. <i>Journal of Urology</i> , 2015, 193, 690-698.	0.4	57

#	ARTICLE	IF	CITATIONS
55	The DHEA-sulfate depot following P450c17 inhibition supports the case for AKR1C3 inhibition in high risk localized and advanced castration resistant prostate cancer. <i>Chemico-Biological Interactions</i> , 2015, 234, 332-338.	4.0	57
56	Neoadjuvant-Intensive Androgen Deprivation Therapy Selects for Prostate Tumor Foci with Diverse Subclonal Oncogenic Alterations. <i>Cancer Research</i> , 2018, 78, 4716-4730.	0.9	56
57	Activation of p21-activated Kinase 6 by MAP Kinase Kinase 6 and p38 MAP Kinase. <i>Journal of Biological Chemistry</i> , 2005, 280, 3323-3330.	3.4	46
58	Contribution of Adrenal Glands to Intratumor Androgens and Growth of Castration-Resistant Prostate Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 426-439.	7.0	46
59	Comparative Genomics Reveals Distinct Immune-oncologic Pathways in African American Men with Prostate Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 320-329.	7.0	46
60	Androgen receptor and MYC equilibration centralizes on developmental super-enhancer. <i>Nature Communications</i> , 2021, 12, 7308.	12.8	46
61	Modulating Androgen Receptor-Driven Transcription in Prostate Cancer with Selective CDK9 Inhibitors. <i>Cell Chemical Biology</i> , 2021, 28, 134-147.e14.	5.2	44
62	Gleason Score 7 Prostate Cancers Emerge through Branched Evolution of Clonal Gleason Pattern 3 and 4. <i>Clinical Cancer Research</i> , 2017, 23, 3823-3833.	7.0	43
63	Tyrosine Kinase Inhibitors Increase MCL1 Degradation and in Combination with BCLXL/BCL2 Inhibitors Drive Prostate Cancer Apoptosis. <i>Clinical Cancer Research</i> , 2018, 24, 5458-5470.	7.0	43
64	Downregulation of <i>Dipeptidyl Peptidase 4</i> Accelerates Progression to Castration-Resistant Prostate Cancer. <i>Cancer Research</i> , 2018, 78, 6354-6362.	0.9	42
65	Developing understanding of the roles of CD1d-restricted T cell subsets in cancer: Reversing tumor-induced defects. <i>Clinical Immunology</i> , 2011, 140, 184-195.	3.2	41
66	ErbB2 Signaling Increases Androgen Receptor Expression in Abiraterone-Resistant Prostate Cancer. <i>Clinical Cancer Research</i> , 2016, 22, 3672-3682.	7.0	39
67	Circulating Myeloid Dendritic Cells of Advanced Cancer Patients Result in Reduced Activation and a Biased Cytokine Profile in Invariant NKT Cells. <i>Journal of Immunology</i> , 2008, 180, 7287-7293.	0.8	38
68	Low Abundance of Circulating Tumor DNA in Localized Prostate Cancer. <i>JCO Precision Oncology</i> , 2019, 3, 1-13.	3.0	36
69	Targeting the androgen receptor and overcoming resistance in prostate cancer. <i>Current Opinion in Oncology</i> , 2019, 31, 175-182.	2.4	36
70	Effect of neoadjuvant abiraterone acetate (AA) plus leuprolide acetate (LHRHa) on PSA, pathological complete response (pCR), and near pCR in localized high-risk prostate cancer (LHRPC): Results of a randomized phase II study.. <i>Journal of Clinical Oncology</i> , 2012, 30, 4521-4521.	1.6	36
71	Activation of Nonreceptor Tyrosine Kinase Bmx/Etk Mediated by Phosphoinositide 3-Kinase, Epidermal Growth Factor Receptor, and ErbB3 in Prostate Cancer Cells. <i>Journal of Biological Chemistry</i> , 2007, 282, 32689-32698.	3.4	32
72	MARCH5 mediates NOXA-dependent MCL1 degradation driven by kinase inhibitors and integrated stress response activation. <i>ELife</i> , 2020, 9, .	6.0	32

#	ARTICLE	IF	CITATIONS
73	Association of Tissue Abiraterone Levels and <i>SLCO</i> Genotype with Intraprostatic Steroids and Pathologic Response in Men with High-Risk Localized Prostate Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 4592-4601.	7.0	31
74	A Phase II Trial of Abiraterone Combined with Dutasteride for Men with Metastatic Castration-Resistant Prostate Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 935-945.	7.0	30
75	Intraepithelial Lymphocytes and Their Recognition of Non-Classical MHC Molecules. <i>International Reviews of Immunology</i> , 1994, 11, 15-30.	3.3	29
76	Positive feedback loop mediated by protein phosphatase 1 \pm mobilization of P-TEFb and basal CDK1 drives androgen receptor in prostate cancer. <i>Nucleic Acids Research</i> , 2017, 45, gkw1291.	14.5	28
77	Evidence of T cell receptor β -chain patterns in inflammatory and noninflammatory bowel disease states. <i>American Journal of Physiology - Renal Physiology</i> , 1999, 276, G613-G621.	3.4	24
78	Androgen Receptor Interaction with Mediator Complex Is Enhanced in Castration-Resistant Prostate Cancer by CDK7 Phosphorylation of MED1. <i>Cancer Discovery</i> , 2019, 9, 1490-1492.	9.4	24
79	Molecular features of exceptional response to neoadjuvant anti-androgen therapy in high-risk localized prostate cancer. <i>Cell Reports</i> , 2021, 36, 109665.	6.4	24
80	Peripheral blood progenitor cell product contains Th1-biased noninvariant CD1d-reactive natural killer T cells: Implications for posttransplant survival. <i>Experimental Hematology</i> , 2008, 36, 464-472.	0.4	23
81	Inhibition of EZH2 transactivation function sensitizes solid tumors to genotoxic stress. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, .	7.1	22
82	Tyrosine Kinase BMX Phosphorylates Phosphotyrosine-Primed Motif Mediating the Activation of Multiple Receptor Tyrosine Kinases. <i>Science Signaling</i> , 2013, 6, ra40.	3.6	21
83	A Subset of Localized Prostate Cancer Displays an Immunogenic Phenotype Associated with Losses of Key Tumor Suppressor Genes. <i>Clinical Cancer Research</i> , 2021, 27, 4836-4847.	7.0	20
84	Protein phosphatase 1 suppresses androgen receptor ubiquitylation and degradation. <i>Oncotarget</i> , 2016, 7, 1754-1764.	1.8	20
85	Phosphorylation of androgen receptor serine 81 is associated with its reactivation in castration-resistant prostate cancer. <i>Cancer Letters</i> , 2018, 438, 97-104.	7.2	19
86	ZBTB7A Mediates the Transcriptional Repression Activity of the Androgen Receptor in Prostate Cancer. <i>Cancer Research</i> , 2019, 79, 5260-5271.	0.9	19
87	Androgen receptor epigenetics. <i>Translational Andrology and Urology</i> , 2013, 2, 148-157.	1.4	19
88	Taxane Resistance in Prostate Cancer Mediated by AR-Independent GATA2 Regulation of IGF2. <i>Cancer Cell</i> , 2015, 27, 158-159.	16.8	17
89	Isolation and Functional Use of Human NKT Cells. <i>Current Protocols in Immunology</i> , 2017, 119, 14.11.1-14.11.20.	3.6	17
90	BMX-Mediated Regulation of Multiple Tyrosine Kinases Contributes to Castration Resistance in Prostate Cancer. <i>Cancer Research</i> , 2018, 78, 5203-5215.	0.9	16

#	ARTICLE	IF	CITATIONS
91	Association of B7 α expression with racial ancestry, immune cell density, and androgen receptor activation in prostate cancer. <i>Cancer</i> , 2022, 128, 2269-2280.	4.1	16
92	Reprogramming to resist. <i>Science</i> , 2017, 355, 29-30.	12.6	15
93	Association Between Androgen Receptor Splice Variants and Prostate Cancer Resistance to Abiraterone and Enzalutamide. <i>Journal of Clinical Oncology</i> , 2017, 35, 2103-2105.	1.6	15
94	Autocrine Canonical Wnt Signaling Primes Noncanonical Signaling through ROR1 in Metastatic Castration-Resistant Prostate Cancer. <i>Cancer Research</i> , 2022, 82, 1518-1533.	0.9	15
95	Genomic Resistance Patterns to Second-Generation Androgen Blockade in Paired Tumor Biopsies of Metastatic Castration-Resistant Prostate Cancer. <i>JCO Precision Oncology</i> , 2017, 1, 1-11.	3.0	13
96	Association of prostate cancer SLCO gene expression with Gleason grade and alterations following androgen deprivation therapy. <i>Prostate Cancer and Prostatic Diseases</i> , 2019, 22, 560-568.	3.9	13
97	Circulating and Intratumoral Adrenal Androgens Correlate with Response to Abiraterone in Men with Castration-Resistant Prostate Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 6001-6011.	7.0	13
98	Androgen receptor splice variant 7 functions independently of the full length receptor in prostate cancer cells. <i>Cancer Letters</i> , 2021, 519, 172-184.	7.2	13
99	Targeting the Intrinsic Apoptosis Pathway: A Window of Opportunity for Prostate Cancer. <i>Cancers</i> , 2022, 14, 51.	3.7	12
100	Mutation Profiling Indicates High Grade Prostatic Intraepithelial Neoplasia as Distant Precursors of Adjacent Invasive Prostatic Adenocarcinoma. <i>Prostate</i> , 2016, 76, 1227-1236.	2.3	11
101	Assessment of Androgen Receptor Splice Variant-7 as a Biomarker of Clinical Response in Castration-Sensitive Prostate Cancer. <i>Clinical Cancer Research</i> , 2022, 28, 3509-3525.	7.0	11
102	Modeling Androgen Deprivation Therapy α -Induced Prostate Cancer Dormancy and Its Clinical Implications. <i>Molecular Cancer Research</i> , 2022, 20, 782-793.	3.4	10
103	Exploiting the tumor-suppressive activity of the androgen receptor by CDK4/6 inhibition in castration-resistant prostate cancer. <i>Molecular Therapy</i> , 2022, 30, 1628-1644.	8.2	10
104	Initiation and Evolution of Early Onset Prostate Cancer. <i>Cancer Cell</i> , 2018, 34, 874-876.	16.8	9
105	Calcium signaling: an underlying link between cardiac disease and carcinogenesis. <i>Cell and Bioscience</i> , 2018, 8, 39.	4.8	9
106	Characteristics of myeloproliferative neoplasms in patients exposed to ionizing radiation following the Chernobyl nuclear accident. <i>American Journal of Hematology</i> , 2019, 94, 62-73.	4.1	9
107	Doxycycline Regulated Induction of AKT in Murine Prostate Drives Proliferation Independently of p27 Cyclin Dependent Kinase Inhibitor Downregulation. <i>PLoS ONE</i> , 2012, 7, e41330.	2.5	9
108	Loss of Wave1 gene defines a subtype of lethal prostate cancer. <i>Oncotarget</i> , 2015, 6, 12383-12391.	1.8	9

#	ARTICLE	IF	CITATIONS
109	Androgen receptor functions in prostate cancer development and progression. Asian Journal of Andrology, 2014, 16, 561.	1.6	9
110	MHC evolution. Nature, 1995, 374, 505-506.	27.8	7
111	Metastatic Castration-Resistant Prostate Cancer Remains Dependent on Oncogenic Drivers Found in Primary Tumors. JCO Precision Oncology, 2021, 5, 1514-1522.	3.0	6
112	A phase Ib study of BKM120 combined with abiraterone acetate for castrate-resistant, metastatic prostate cancer.. Journal of Clinical Oncology, 2015, 33, 274-274.	1.6	6
113	Has the Time Arrived for Biomarker-Directed Therapy in Castration-Resistant Prostate Cancer?. JAMA Oncology, 2015, 1, 577.	7.1	5
114	Specific reversal of cytolytic T lymphocyte - target cell interaction. Journal of Supramolecular Structure and Cellular Biochemistry, 1981, 16, 43-52.	1.4	3
115	Neoadjuvant androgen pathway suppression prior to prostatectomy.. Journal of Clinical Oncology, 2012, 30, 4520-4520.	1.6	3
116	Circulating Cell-Free DNA as Biomarker of Taxane Resistance in Metastatic Castration-Resistant Prostate Cancer. Cancers, 2021, 13, 4055.	3.7	1
117	A phase Ib study of BKM120 combined with abiraterone acetate for castrate-resistant, metastatic prostate cancer.. Journal of Clinical Oncology, 2014, 32, TPS2641-TPS2641.	1.6	1
118	Association of SLCO transport genes with intraprostatic abiraterone (ABI) levels and pathologic outcomes in men with high-risk localized prostate cancer (PCa).. Journal of Clinical Oncology, 2015, 33, 5013-5013.	1.6	1
119	A phase II study of nivolumab in patients with high-risk biochemically recurrent (BCR) prostate cancer (PCa).. Journal of Clinical Oncology, 2019, 37, TPS341-TPS341.	1.6	1
120	A Case of Prostate Cancer Harboring Androgen Receptor T878A Progesterone-Responsive Mutant Emerging After Abiraterone Acetate Treatment Responding to Darolutamide. JCO Precision Oncology, 2022, 6, e2100091.	3.0	1
121	Immune mechanisms behind prostate cancer in men of African ancestry: A review. Prostate, 2022, 82, 883-893.	2.3	1
122	Invariant NKT cell-augmented GM-CSF-secreting tumor vaccine is effective in advanced prostate cancer model. Cancer Immunology, Immunotherapy, 2022, , .	4.2	1
123	In Vitro Generation of Highly-Purified Functional Invariant NKT Cells: A Strategy for Immunotherapy in Multiple Myeloma.. Blood, 2005, 106, 5183-5183.	1.4	0
124	In Vitro Generation of Highly Purified Functional Invariant NKT Cells in Multiple Myeloma: A Strategy for Immunotherapy.. Blood, 2006, 108, 5104-5104.	1.4	0
125	Association of serum (SR) and tissue (TX) abiraterone (ABI) levels with intraprostatic steroids and pathologic outcomes in men with high-risk localized prostate cancer (PCa).. Journal of Clinical Oncology, 2014, 32, 5015-5015.	1.6	0
126	Fine tuning metabolism of biochemically active abiraterone metabolites to optimize anti-androgen therapy in prostate cancer.. Journal of Clinical Oncology, 2016, 34, 5016-5016.	1.6	0

#	ARTICLE	IF	CITATIONS
127	Genomic mechanisms of resistance to neoadjuvant leuprolide plus abiraterone in locally advanced prostate cancer.. Journal of Clinical Oncology, 2017, 35, 98-98.	1.6	0
128	Measurement science of the androgen receptor splice variant-7 protein in primary and castration-resistant prostate cancer tissue.. Journal of Clinical Oncology, 2019, 37, 151-151.	1.6	0
129	Circulating-free DNA (cfDNA) as biomarker of taxane resistance in metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2020, 38, 174-174.	1.6	0